Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients
Chidamide With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide for Peripheral T Cell Lymphoma Patients : a Prospective, Randomized Controlled, Open Label, Phase II Clinical Trial
Experimental Tumor
DRUG: Chidamide|DRUG: Cyclophosphamide|DRUG: Doxorubicin|DRUG: Vincristine|DRUG: Etoposide|DRUG: Prednisone
complete remission (CR）rate, The rate of patients who achieve complete remission after the treatment., up to 2 years
objective response rate（ORR）, The total proportion of patients with complete response（CR）and partial response（PR）., up to 2 years|progression-free survival（PFS）, Time from treatment until disease progression or death., 2 years|overall survival（OS）, From the date of inclusion to date of death, irrespective of any cause., 2 years after the last patient's enrollment.
Chidamide，a novel histone deacetylase inhibitor has been approved for the treatment of relapsed or refractory peripheral T-cell lymphoma in China. The aim of this study was to observe the efficacy and safety of Chidamide With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide for Peripheral T Cell Lymphoma Patients.